CERO THERAPEUTICS HOLDINGS, INC.

CERO Therapeutics Holdings, Inc. (Nasdaq: CERO) is a clinical-stage biopharmaceutical company focused on developing chimeric engulfment receptor T-cell (CER-T) therapies for oncology indications. The company became publicly traded in early 2023 through its business combination with Phoenix Biotech Acquisition Corp (Nasdaq: PBAX), a blank-check company that completed its IPO in 2021 and was sponsored by Phoenix Biotech Sponsor LLC. The July 2026 Form 424B3 filing represents a prospectus supplement associated with the company's registered securities. CERO operates in the cell therapy and immuno-oncology sector, advancing its proprietary platform designed to harness macrophage-mediated engulfment of tumor cells. Visit SpacDesk and sign up for full data, filings, and deal analytics on CERO and hundreds of other SPAC transactions.